Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) Operating Income (2020 - 2025)

Lyell Immunopharma (LYEL) has disclosed Operating Income for 6 consecutive years, with -$127.6 million as the latest value for Q4 2025.

  • Quarterly Operating Income rose 36.54% to -$127.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$269.4 million through Dec 2025, up 24.91% year-over-year, with the annual reading at -$269.4 million for FY2025, 24.91% up from the prior year.
  • Operating Income hit -$127.6 million in Q4 2025 for Lyell Immunopharma, down from -$37.3 million in the prior quarter.
  • In the past five years, Operating Income ranged from a high of -$14.8 million in Q4 2022 to a low of -$201.1 million in Q4 2024.
  • Historically, Operating Income has averaged -$63.9 million across 5 years, with a median of -$56.5 million in 2024.
  • Biggest five-year swings in Operating Income: soared 68.9% in 2022 and later tumbled 302.52% in 2023.
  • Year by year, Operating Income stood at -$47.5 million in 2021, then skyrocketed by 68.9% to -$14.8 million in 2022, then crashed by 302.52% to -$59.5 million in 2023, then crashed by 238.02% to -$201.1 million in 2024, then soared by 36.54% to -$127.6 million in 2025.
  • Business Quant data shows Operating Income for LYEL at -$127.6 million in Q4 2025, -$37.3 million in Q3 2025, and -$47.1 million in Q2 2025.